- Home
- ABEO vs NHS Comparison
ABEO vs NHS Comparison
Compare ABEO & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- NHS
- Stock Information
- Founded
- ABEO N/A
- NHS 2003
- Country
- ABEO United States
- NHS United States
- Employees
- ABEO N/A
- NHS N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- NHS Trusts Except Educational Religious and Charitable
- Sector
- ABEO Health Care
- NHS Finance
- Exchange
- ABEO Nasdaq
- NHS Nasdaq
- Market Cap
- ABEO 237.4M
- NHS 221.6M
- IPO Year
- ABEO 1980
- NHS N/A
- Fundamental
- Price
- ABEO $4.68
- NHS $7.67
- Analyst Decision
- ABEO Strong Buy
- NHS
- Analyst Count
- ABEO 5
- NHS 0
- Target Price
- ABEO $17.00
- NHS N/A
- AVG Volume (30 Days)
- ABEO 503.6K
- NHS 111.8K
- Earning Date
- ABEO 03-20-2025
- NHS 01-01-0001
- Dividend Yield
- ABEO N/A
- NHS 13.44%
- EPS Growth
- ABEO N/A
- NHS N/A
- EPS
- ABEO N/A
- NHS N/A
- Revenue
- ABEO N/A
- NHS N/A
- Revenue This Year
- ABEO N/A
- NHS N/A
- Revenue Next Year
- ABEO $561.86
- NHS N/A
- P/E Ratio
- ABEO N/A
- NHS N/A
- Revenue Growth
- ABEO N/A
- NHS N/A
- 52 Week Low
- ABEO $3.05
- NHS $6.95
- 52 Week High
- ABEO $8.45
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- ABEO 36.32
- NHS 45.48
- Support Level
- ABEO $4.42
- NHS $7.59
- Resistance Level
- ABEO $5.14
- NHS $7.72
- Average True Range (ATR)
- ABEO 0.25
- NHS 0.06
- MACD
- ABEO -0.05
- NHS -0.00
- Stochastic Oscillator
- ABEO 25.24
- NHS 59.37
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.